Skip to main content

Table 8 Evaluation of efficacy

From: Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis

 CureImprovedInvalidity or deteriorationEffective cases (Effective rate)
End of treatment(6 months)116317/20(85%)
End of follow-up (12 months)014314/17(82.35%)